Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Abstract Background The identification of biomarkers to select patients with metastatic renal cell carcinoma (mRCC) most likely to respond to combination immunotherapy (IO) is needed. We sought to investigate an association of the baseline neutrophil-to-eosinophil ratio (NER) with outcomes to nivolu...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Matthew D. Tucker, Landon C. Brown, Yu-Wei Chen, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Kristin K. Ancell, Kathryn E. Beckermann, Nancy B. Davis, Renee McAlister, Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, W. Kimryn Rathmell, Brian I. Rini, Tian Zhang
Format: article
Langue:EN
Publié: BMC 2021
Sujets:
Kidney neoplasms
Immunotherapy
Tumor biomarkers
Therapeutics. Pharmacology
RM1-950
Accès en ligne:https://doaj.org/article/046d21ea12ea41aeaea7c6d824b8b8a6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/046d21ea12ea41aeaea7c6d824b8b8a6

Documents similaires